a. 1000 – 1500 cGy
b. 1500 – 2000 cGy
c. 2000 – 2500 cGy
d. 2500 – 3000 cGy
17q: what is the major long term effect of standard ( modified bilateral ) RPLND operation ?
a. retrograde ejaculation and infertility
b. urinary incontinence
c. fecal incontinence
d. lymphedema of leg
18q: what are the doses of etoposide and cisplatin in the treatment of high volume metastasis of stage II nonseminoma ?
a. 100 mg/sq.m daily on days 1-5 and 20 mg/sq.m daily on days 1-5 respectively
b. 50 mg/sq.m daily on days 1-5 and 10 mg/sq.m daily on days 1-5 respectively
c. 200 mg/sq.m daily on days 1-5 and 50 mg/sq.m daily on days 1-5 respectively
d. 10 mg/sq.m daily on days 1-5 and 80 mg/sq.m daily on days 1-5 respectively
19q: which of the following is second line chemotherapy used in 20 – 30 % patients with advanced GCT, who fail to achieve a durable complete response to first line chemotherapy ?
a. cisplatin , ifosfamide and vinblastine ( VeIP)
b. cisplatin , bleomycin and vincristine
c. etoposide , cisplatin and chlorambucil
d. ifosfamide , bleomycin and etoposide
20q: what is the treatment of choice in advanced GCT patients who have progressed even after taking ifosfamide containing salvage chemotherapy ( VeIP ) ?
a. dose intensive , high dose cisplatin ( 1500 mg/m2 ) plus etoposide ( 1200 mg/m2 ) with or without cyclophosphamide or ifosfamide with peripheral blood stem cell support
b. dose intensive , high dose carboplatin( 1500 mg/m2 ) plus etoposide ( 1200 mg/m2 ) with or without cyclophosphamide or ifosfamide with peripheral blood stem cell support
c. dose intensive , high dose vinblastine ( 1500 mg/m2 ) plus etoposide ( 1200 mg/m2 ) with or without cyclophosphamide or ifosfamide with peripheral blood stem cell support
d. dose intensive , high dose carboplatin( 1500 mg/m2 ) plus bleomycin ( 1200 mg/m2 ) with or without cyclophosphamide or ifosfamide with peripheral blood stem cell support
